For this reason, B7-H3 inhibitors, such as enoblituzumab, are under clinical investigation in several phase I and II trials in metastatic PC, with promising preliminary results [130] (NCT02628535, NCT02923180, NCT01391143). The gene discussed is CD276; the disease is pachyonychia congenita.